View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 1, 2020

Gilead’s remdesivir a candidate for US government stockpiling or bulk buying in private sector

By Victoria Smith

Remdesivir, Gilead Sciences ‘ drug, could be under consideration to be added to the classified US Strategic National Stockpile (SNS), as well as individual states’ stockpiles, in the event donated doses exhaust and Covid-19 cases outstrip supply.

According to a 1 May company press release, Gilead’s donated of 1.5 million individual remdesivir doses adds up to more than 140,000 treatment courses (assuming a 10-day treatment course). Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology